Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment

Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment

Diabetic macular edema (DME) is the most common cause of moderate visual loss in diabetic patients. The current treatment of choice for center-involved DME is anti-vascular endothelial growth factor (VEGF) treatment. Most patients that undergo pharmacological inhibition with anti-VEGF agents need mu...

Full description

Bibliographic Details
Main Authors: Stephanie Flikier, Andres Wu, Lihteh Wu
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Taiwan Journal of Ophthalmology
Subjects:
aflibercept
bevacizumab
diabetic macular edema
laser photocoagulation
oxygen
pars plana vitrectomy
ranibizumab
vascular endothelial growth factor
vitreomacular traction
Online Access:http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=224;epage=232;aulast=Flikier

Internet

http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=224;epage=232;aulast=Flikier

Similar Items